CN117137924A - Application of N-acetyl-D-mannosamine in preparation of food and medicine for promoting bone growth - Google Patents
Application of N-acetyl-D-mannosamine in preparation of food and medicine for promoting bone growth Download PDFInfo
- Publication number
- CN117137924A CN117137924A CN202311276869.4A CN202311276869A CN117137924A CN 117137924 A CN117137924 A CN 117137924A CN 202311276869 A CN202311276869 A CN 202311276869A CN 117137924 A CN117137924 A CN 117137924A
- Authority
- CN
- China
- Prior art keywords
- bone
- mannosamine
- acetyl
- cells
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- OVRNDRQMDRJTHS-ZTVVOAFPSA-N N-acetyl-D-mannosamine Chemical compound CC(=O)N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-ZTVVOAFPSA-N 0.000 title claims abstract description 80
- 230000001737 promoting effect Effects 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 230000008468 bone growth Effects 0.000 title claims abstract description 17
- 235000013305 food Nutrition 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 5
- 210000004027 cell Anatomy 0.000 claims abstract description 54
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 43
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 26
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- 210000002966 serum Anatomy 0.000 claims abstract description 16
- 230000011164 ossification Effects 0.000 claims abstract description 15
- 230000001965 increasing effect Effects 0.000 claims abstract description 12
- 230000002308 calcification Effects 0.000 claims abstract description 11
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 11
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 claims abstract description 8
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 8
- 230000002708 enhancing effect Effects 0.000 claims abstract description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 13
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 13
- 208000006386 Bone Resorption Diseases 0.000 claims description 10
- 230000024279 bone resorption Effects 0.000 claims description 9
- 101710190440 Cytotoxin 1 Proteins 0.000 claims description 7
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 claims description 7
- VYVRIXWNTVOIRD-LRHBOZQDSA-N ciguatoxin CTX1B Chemical compound C([C@@]12[C@@H](C)[C@@H]([C@@H]3[C@H]([C@H]([C@H](C)[C@H]4O[C@H]5C[C@@H](C)C[C@H]6O[C@@]7(C)[C@H](O)C[C@H]8O[C@H]9C=C[C@H]%10O[C@H]%11C[C@@H]%12[C@H]([C@@H]([C@H]%13O[C@H](C=CC[C@@H]%13O%12)\C=C\[C@H](O)CO)O)O[C@@H]%11C=C[C@@H]%10O[C@@H]9C\C=C/C[C@@H]8O[C@@H]7C[C@@H]6O[C@@H]5C[C@@H]4O3)O)O2)C)[C@H](O)CO1 VYVRIXWNTVOIRD-LRHBOZQDSA-N 0.000 claims description 7
- 208000020084 Bone disease Diseases 0.000 claims description 6
- 230000002188 osteogenic effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000006184 cosolvent Substances 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 230000009818 osteogenic differentiation Effects 0.000 claims description 3
- -1 pH regulator Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 241000792859 Enema Species 0.000 claims description 2
- 208000029725 Metabolic bone disease Diseases 0.000 claims description 2
- 206010049088 Osteopenia Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000007920 enema Substances 0.000 claims description 2
- 229940095399 enema Drugs 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 235000021056 liquid food Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 208000005368 osteomalacia Diseases 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 208000007442 rickets Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 235000021055 solid food Nutrition 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 22
- 241000699666 Mus <mouse, genus> Species 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000003405 preventing effect Effects 0.000 abstract description 9
- 238000011161 development Methods 0.000 abstract description 8
- 230000014461 bone development Effects 0.000 abstract description 5
- 239000003550 marker Substances 0.000 abstract description 5
- 230000002829 reductive effect Effects 0.000 abstract description 5
- 230000018109 developmental process Effects 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 230000012010 growth Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 238000011269 treatment regimen Methods 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 33
- 238000009806 oophorectomy Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 108090000573 Osteocalcin Proteins 0.000 description 10
- 102000004067 Osteocalcin Human genes 0.000 description 7
- 230000001936 parietal effect Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 6
- 210000000963 osteoblast Anatomy 0.000 description 6
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010832 independent-sample T-test Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000013322 soy milk Nutrition 0.000 description 3
- 210000000689 upper leg Anatomy 0.000 description 3
- 101150079550 BSP gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 101150086605 Runx2 gene Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 235000007270 Gaultheria hispida Nutrition 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000009134 Myrica cerifera Nutrition 0.000 description 1
- 244000269152 Myrica pensylvanica Species 0.000 description 1
- 235000012851 Myrica pensylvanica Nutrition 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 101000774651 Naja atra Zinc metalloproteinase-disintegrin-like kaouthiagin-like Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 102000014128 RANK Ligand Human genes 0.000 description 1
- 108010025832 RANK Ligand Proteins 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 102000007591 Tartrate-Resistant Acid Phosphatase Human genes 0.000 description 1
- 108010032050 Tartrate-Resistant Acid Phosphatase Proteins 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- MBLBDJOUHNCFQT-WCTZXXKLSA-N aldehydo-N-acetyl-D-mannosamine Chemical compound CC(=O)N[C@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-WCTZXXKLSA-N 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 125000005340 bisphosphate group Chemical group 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108091006084 receptor activators Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses an application of N-acetyl-D-mannosamine in preparing foods and medicines for promoting bone growth, belonging to the field of biomedical foods. The present invention finds that N-acetyl-D-mannosamine is capable of: (1) Enhancing ALP activity and calcification degree of human bone marrow mesenchymal stem cells H-BMSC and mouse cranio-apical prebone cells; (2) up-regulating the expression of osteogenesis-related genes RUNX2, OCN and BSP; (3) The serum bone formation marker content of the mice in the osteoporosis model group is increased, the serum bone absorption marker content is reduced, the bone quantity, the thickness and the number of the trabeculae are increased, and the trabeculae clearance is reduced. The invention proves that the N-acetyl-D-mannosamine has the function of promoting bone growth and development and resisting osteoporosis. The invention provides a new theoretical basis for researching osteoporosis treatment strategies and provides a new scheme for preparing new medicaments or functional foods for promoting growth and development of teenagers bones and preventing or treating osteoporosis.
Description
Technical Field
The invention relates to an application of N-acetyl-D-mannosamine in preparing foods and medicines for promoting bone growth, belonging to the field of biomedical foods.
Background
Osteoporosis (OP) is a systemic skeletal disease characterized by reduced bone mass, increased bone fragility and increased risk of fracture due to destruction of the microstructure of bone tissue. Osteoporosis has become an important health problem for people over 50 years old, the prevalence of osteoporosis in people over 50 years old is 19.2%, and osteoporosis has become a non-negligible health problem.
Current clinical prophylaxis and treatment methods for osteoporosis include altering risk factors, calcium and vitamin D supplementation, physical exercise, and drug therapy to maintain bone mass or stimulate new bone formation to maximize skeletal and muscle strength, improve balance, and minimize risk of osteoporotic fracture. The medicines for preventing and treating osteoporosis clinically mainly comprise the following three types: anti-bone resorption drugs such as bisphosphates, calcitonin, nuclear factor- κb receptor activator ligand (RANKL) inhibitor diels, etc.; drugs for promoting bone formation, such as parathyroid hormone analogues, vitamin K-like compounds, etc.; other mechanisms are drugs. However, the above drugs widely have obvious side effects such as gastrointestinal adverse reactions, hepatotoxicity, jawbone necrosis, induced cancers, cardiovascular diseases and the like. Therefore, there is an urgent need to find ways and products to effectively control OP.
Mannosamine is 8 carbonic acid amino sugar, is a precursor molecule in sialic acid biosynthesis pathway, and is used as a biological endogenous active substance, and modern researches show that N-acetyl-D-mannosamine is safe and has no toxic or side effect. In mammals, N-acetyl-D-mannosamine is an important precursor for glycosylation modification. Through linkage with hydroxyl groups in proteins and lipids, participate in glycosylation modification reactions on the cell surface and in other tissues in the body, thereby altering the structure and function of these molecules. The prior art discloses that exogenously supplementing N-acetyl-D-mannosamine can regulate immunity, improve sugar metabolism, repair gastric mucosa, lubricate joints, etc., however, no research on N-acetyl-D-mannosamine has been conducted on the aspects of promoting bone growth and development and resisting osteoporosis.
Disclosure of Invention
[ technical problem ]
The technical problem to be solved by the invention is that the prior art has no effect of N-acetyl-D-mannosamine in promoting bone growth and development and preventing or treating osteoporosis and application research.
Technical scheme
Aiming at the defects of the prior art, the invention aims to provide a new application of N-acetyl-D-mannosamine, in particular to the application of N-acetyl-D-mannosamine in preparing medicines and foods for promoting bone growth.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
a first object of the present invention is to provide the use of N-acetyl-D-mannosamine or a pharmaceutically acceptable salt thereof for the preparation of a product for promoting bone growth and/or for alleviating and/or treating bone diseases.
In one embodiment of the present invention, the N-acetyl-D-mannosamine has the structural formula:
in one embodiment of the invention, the promoting bone growth comprises promoting adolescent skeletal growth.
In one embodiment of the invention, the bone disease comprises osteomalacia, rickets, osteopenia or osteoporosis.
In one embodiment of the invention, the product comprises a pharmaceutical or food product.
In one embodiment of the present invention, the dosage form of the drug includes any one of suspension, granule, capsule, powder, tablet, emulsion, solution, drop pill, injection, suppository, enema, aerosol, patch or drop.
In one embodiment of the invention, the medicament further comprises a pharmaceutically acceptable excipient.
In one embodiment of the present invention, the adjuvant comprises any one or a combination of at least two of a carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, co-solvent, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH regulator, antioxidant, bacteriostatic agent or buffer.
In one embodiment of the present invention, the combination of at least two of the above-mentioned components, such as a combination of a diluent and an excipient, a combination of a binder and a wetting agent, a combination of an emulsifier and a cosolvent, etc., may be selected in any other combination.
In one embodiment of the invention, the route of administration of the drug comprises oral administration, sublingual administration, rectal administration, dermal mucosa administration, inhalation administration or injection administration.
In one embodiment of the invention, the food product comprises a nutraceutical or a dietary supplement.
In one embodiment of the invention, the food product comprises a solid food product, a liquid food product or a semi-solid food product.
In one embodiment of the invention, the food product comprises a dairy product, a soy product or a fruit and vegetable product.
In one embodiment of the invention, the dairy product comprises a fermented dairy product, a milk-containing beverage, and a milk powder.
In one embodiment of the invention, the soy product comprises soy milk, soy milk drink, soy milk powder.
In one embodiment of the invention, the fruit and vegetable products comprise beet, cabbage, carrot, white radish, kelp, cucumber, yellow peach, litchi and waxberry products.
In one embodiment of the invention, the promotion of bone growth, and/or alleviation and/or treatment of bone disease comprises the effects of at least one of the following (a) - (e):
(a) Enhancing alkaline phosphatase activity of bone marrow mesenchymal stem cells and/or cranio-parietal preastes cells, and/or osteogenic gene RUNX2, OCN, BSP expression level, and/or degree of calcification, and/or osteogenic differentiation;
(b) Increasing serum bone formation markers PINP and/or BALP content;
(c) Reducing the content of serum bone resorption markers CTX-1 and/or TRAP;
(d) Increasing bone mass and/or the number of bone trabeculae;
(e) Reducing bone trabecular clearance.
Compared with the prior art, the invention has the following beneficial effects:
the invention discovers that N-acetyl-D-mannosamine has certain effects on promoting bone growth and development and preventing or treating osteoporosis for the first time:
(1) The invention discovers that N-acetyl-D-mannosamine can enhance the differentiation capacity of human bone marrow mesenchymal stem cells H-BMSC and mouse cranium top preosteoblast MC3T3-E1Subclone 14 to osteoblasts, and shows that the activity and calcification degree of alkaline phosphatase (ALP) of human bone marrow mesenchymal stem cells H-BMSC and mouse cranium top preosteoblast MC3T3-E1Subclone 14 are promoted, and the specific embodiments are as follows:
a) ALP relative activity in H-BMSC cells was 2.5, 3.2 and 3.4 times that in control groups in low, medium and high dose groups, respectively; the calcification levels of the low, medium and high dose groups were 3.1, 3.7 and 4.5 times, respectively, that of the control group.
b) ALP relative activity in MC3T3-E1Subclone 14 cells was 2.2, 3.0 and 3.5 times that in control groups for low, medium and high dose groups, respectively; the calcification levels of the low, medium and high dose groups were 2.8, 3.5 and 4.4 times that of the control group cells, respectively.
(2) The invention discovers that N-acetyl-D-mannosamine can enhance the differentiation capacity of human bone marrow mesenchymal stem cells H-BMSC and mouse cranio-parietal anterior bone cells MC3T3-E1Subclone 14 to osteoblasts, and is expressed by promoting up-regulation of the expression of bone related protein genes RUNX2, osteocalcin (OCN) and bone sialic acid protein (BSP), and is specifically expressed as follows:
c) In the H-BMSC cells, the expression level of the OCN gene in the low, medium and high dose experimental groups is respectively improved by 1.7 times, 2.3 times and 2.8 times compared with that in the control group; compared with a control group, the BSP gene expression quantity is respectively improved by 2.2 times, 3.3 times and 3.9 times; the RUNX2 gene expression levels were increased by 2.9, 3.6 and 4.0 times, respectively, compared to the control group.
d) In MC3T3-E1Subclone 14 cells, the expression level of OCN genes in low, medium and high dose experimental groups is respectively improved by 1.9 times, 2.7 times and 3.1 times compared with that in a control group; compared with a control group, the BSP gene expression quantity is respectively improved by 1.9 times, 2.8 times and 3.2 times; the RUNX2 gene expression levels were increased by 2.4, 2.8 and 3.2 times, respectively, compared to the control group.
(3) The invention discovers that N-acetyl-D-mannosamine can increase the serum bone formation marker content of an osteoporosis model group mouse subjected to ovariectomy modeling, reduce the serum bone absorption marker content, and can resist osteoporosis in vivo, and the method is specifically shown as follows:
e) The bone formation markers PINP and BALP of the mice in the N-acetyl-D-mannosamine intervention group are obviously improved compared with the mice in the model group, and the bone resorption markers CTX-1 and TRAP are obviously reduced.
f) The Micro-CT results further demonstrate that it has the effect of increasing bone mass and bone trabecular thickness and number, decreasing bone trabecular clearance, and that the direct bone mass (BV/TV), the bone indirect bone mass (BS/TV), the bone trabecular clearance (tb.sp), and the bone trabecular number (tb.n) of the N-acetyl-D-mannosamine-intervention group mice all recovered to the level of the control group, compared to the model group.
The invention provides a new theoretical basis for researching osteoporosis treatment strategies and provides a new scheme for preparing new medicaments or functional foods for promoting growth and development of teenagers bones and preventing or treating osteoporosis.
Drawings
FIG. 1 is a chemical structure diagram of N-acetyl-D-mannosamine according to the present invention;
FIG. 2 is a graph showing the quantitative results of ALP activity in H-BMSC cells (H group) and MC3T3-E1Subclone 14 cells (M group) provided in example 1 of the present invention, which were treated with low dose of N-acetyl-D-mannosamine, medium dose of N-acetyl-D-mannosamine and high dose of N-acetyl-D-mannosamine for 7 days;
FIG. 3 is a graph showing alizarin red staining results of H-BMSC cells (group H) provided in example 1 of the present invention, which were treated with low-dose N-acetyl-D-mannosamine, medium-dose N-acetyl-D-mannosamine, and high-dose N-acetyl-D-mannosamine for 21 days;
FIG. 4 is a graph showing the relative degree of calcification of MC3T3-E1Subclone 14 cells (group M) as provided in example 1 of the present invention upon treatment with low dose N-acetyl-D-mannosamine, medium dose N-acetyl-D-mannosamine and high dose N-acetyl-D-mannosamine for 21 days;
FIG. 5 is a graph showing quantitative alizarin red staining results of H-BMSC cells (H group) and MC3T3-E1Subclone 14 cells (M group) provided in example 1 of the present invention, which were treated with low dose N-acetyl-D-mannosamine, medium dose N-acetyl-D-mannosamine and high dose N-acetyl-D-mannosamine for 21 days;
FIG. 6 is a statistical plot (OCN) of real-time fluorescent quantitative PCR results of H-BMSC cells (H group) and MC3T3-E1Subclone 14 cells (M group) provided in example 2 of the present invention, treated with low dose N-acetyl-D-mannosamine and high dose N-acetyl-D-mannosamine for 7 days;
FIG. 7 is a statistical plot (BSP) of real-time fluorescent quantitative PCR results of H-BMSC cells (H-group) and MC3T3-E1Subclone 14 cells (M-group) provided in example 2 of the present invention, treated with low dose of N-acetyl-D-mannosamine and high dose of N-acetyl-D-mannosamine for 7 days;
FIG. 8 is a statistical plot of real-time fluorescent quantitative PCR results (RUNX 2) of H-BMSC cells (H group) and MC3T3-E1Subclone 14 cells (M group) provided in example 2 of the present invention, treated with low dose of N-acetyl-D-mannosamine and high dose of N-acetyl-D-mannosamine for 7 days;
FIG. 9 is a femur CT image of the C57 mice provided in example 3 of the present invention, respectively perfused with low and high doses of N-acetyl-D-mannosamine for 6 weeks after ovariectomy;
FIG. 10 is a graph showing the results of 6 weeks of direct femoral bone fracture (BV/TV) of low and high doses of N-acetyl-D-mannosamine, respectively, gavaged after ovariectomy in C57 mice provided in example 3 of the present invention;
FIG. 11 is a graph showing results of 6 weeks of intertrochanteric bone fracture (BS/TV) in C57 mice provided in example 3 of the present invention after ovariectomy with low and high doses of N-acetyl-D-mannosamine, respectively;
FIG. 12 is a graph showing the results of 6 weeks of femoral trabecular space (Tb.Sp) between low-dose N-acetyl-D-mannosamine and high-dose N-acetyl-D-mannosamine, respectively, obtained from the ovariectomy of C57 mice provided in example 3 of the present invention;
FIG. 13 is a graph showing the results of 6 weeks after ovariectomy of the C57 mice provided in example 3 of the present invention, of the number of femoral trabeculae (Tb.n) in the stomach of the low dose of N-acetyl-D-mannosamine and the high dose of N-acetyl-D-mannosamine, respectively;
FIG. 14 is a graph showing the results of the PINP levels of the serum bone formation markers obtained after 6 weeks of the respective gastric lavage of low-dose N-acetyl-D-mannosamine and high-dose N-acetyl-D-mannosamine after ovariectomy of the C57 mice provided in example 3 of the present invention;
FIG. 15 is a graph showing the results of BALP content of serum bone formation markers for 6 weeks after ovariectomy of C57 mice provided in example 3 of the present invention, respectively, with low and high doses of N-acetyl-D-mannosamine;
FIG. 16 is a graph showing the results of the content of CTX-1, a serum bone resorption marker, for 6 weeks after ovariectomy of C57 mice provided in example 3 of the present invention, in the stomach of low-dose N-acetyl-D-mannosamine and high-dose N-acetyl-D-mannosamine, respectively;
FIG. 17 is a graph showing the results of the TRAP content of serum bone resorption markers obtained by 6 weeks after ovariectomizing C57 mice provided in example 3 of the present invention, respectively, by gastric lavage of low-dose N-acetyl-D-mannosamine and high-dose N-acetyl-D-mannosamine.
Detailed Description
The technical scheme of the invention is further described by the following specific embodiments. It will be apparent to those skilled in the art that the embodiments described are merely to aid in understanding the invention and should not be construed as limiting the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
N-acetyl-D-mannosamine according to the following examples was purchased from MCE under the model HY-128850; human mesenchymal stem cells H-BMSC and mouse parietal anterior bone cell Subclone14 (MC 3T3-E1Subclone 14) were purchased from the Withanbozier life technologies Co., ltd; c57BL/6J mice were purchased from Jiangsu Jiujia kang Biotechnology Co., ltd; alpha-MEM medium was purchased from the Lifescience and technology Co., ltd.
Example 1 effect of N-acetyl-D-mannosamine on osteogenic differentiation of human bone marrow mesenchymal stem cells H-BMSC cells and mouse parietal anterior bone MC3T3-E1Subclone 14 cells.
Human bone marrow mesenchymal stem cells H-BMSC and mouse cranio-parietal anterior bone MC3T3-E1Subclone 14 cells were plated at 2X 10 per well 5 Cell numbers were plated on 12-well plates, after cell attachment, the supernatant was aspirated and alpha-MEM medium containing 10% Fetal Bovine Serum (FBS) and 1% diantigen (penicillin and streptomycin) was added.
TABLE 1 grouping of experiments
The low dose experimental group was added with N-acetyl-D-mannosamine at a final concentration of 10. Mu.g/ml, the medium dose group was added with the same volume of N-acetyl-D-mannosamine at a final concentration of 20. Mu.g/ml, the high dose group was added with the same volume of N-acetyl-D-mannosamine at a final concentration of 50. Mu.g/ml, the control group was added with the corresponding volume of PBS at 2 days later, and the corresponding fresh medium was replaced for each group. After induction for 7 days, the medium was discarded, PBS was washed 3 times, and cells were collected, and alkaline phosphatase (ALP) activity was measured using a cell alkaline phosphatase assay kit, and the results are shown in FIG. 2. After 21 days of induction, the medium was discarded, the cells were fixed with 4% paraformaldehyde after washing with PBS, stained with alizarin red staining solution, and the stained cells were lysed with cetylpyridine and absorbance detection was performed, and the results are shown in FIG. 3.
As can be seen from fig. 2: compared with the control group, the N-acetyl-D-mannosamine with low, medium and high doses has the capacity of inducing the differentiation of H-BMSC cells (H group) and mouse parietal anterior bone MC3T3-E1Subclone 14 cells (M group) towards osteoblasts, which is shown by the increase of ALP activity and the increase of calcification degree. The relative values of ALP activity of H-BMSC cells in the low, medium and high dose groups are 2.5, 3.2 and 3.4 times that of the control group, respectively, and the relative values of ALP activity of MC3T3-E1Subclone 14 cells in the low, medium and high dose groups are 2.2, 3.0 and 3.5 times that of the control group.
As can be seen from fig. 3-5: the low, medium and high doses of N-acetyl-D-mannosamine all had the ability to induce differentiation of H-BMSC cells (H group) and mouse parietal anterior bone MC3T3-E1Subclone 14 cells (M group) towards osteoblasts, showing an increased degree of calcification, compared to the control group. The calcification degree of H-BMSC cells in the low, medium and high dose groups is 3.1, 3.7 and 4.5 times that of the cells in the control group, and the calcification degree of MC3T3-E1Subclone 14 cells in the low, medium and high dose groups is 2.8, 3.5 and 4.4 times that of the cells in the control group
From this, N-acetyl-D-mannosamine can significantly promote differentiation of H-BMSC cells and mouse parietal anterior bone MC3T3-E1Subclone 14 cells to osteoblasts.
The significant differences in the figures are expressed as: "#" and "x" indicate comparison to the H control group and the M control group, respectively, wherein "#" and "x" < 0.05; "#" and "x" < 0.01; "# #" and "x" < 0.001; the analysis method adopted is independent sample T test. EXAMPLE 2 Effect of N-acetyl-D-mannosamine on the expression level of osteogenic Gene
Human mesenchymal stem cells H-BMSC and mouse parietal anterior bone MC3T3-E1Subclone 14 cells were plated at 5X 10 per well 5 Cell numbers were plated on 6-well plates and after cell attachment, replaced with a-MEM medium containing 10% fbs and 1% diabody. The experimental group was the same as in example 1, the low dose group was added with N-acetyl-D-mannosamine in a final concentration of 10. Mu.g/ml, the medium dose group was added with the same volume of N-acetyl-D-mannosamine in the medium, the final concentration was controlled to 20. Mu.g/ml, the high dose group was added with the same volume of N-acetyl-D-mannosamine in the medium, and the final concentration was controlled to 50. Mu.g/ml. The control group was added with the corresponding volume of PBS, and after 2 days each group was replaced with the corresponding fresh medium, the medium was discarded after 21 days of induction, and the PBS was washed 3 times.
Adding 900 mu L of TRIZOL to lyse cells in each hole, transferring the cells to a 1.5mL enzyme-free centrifuge tube, adding 180 mu L of chloroform to the lysate, fully shaking, standing for 10min, and centrifuging at 12000rpm for 15min; adding isopropanol with the same volume into the supernatant, uniformly mixing, standing for 10min, centrifuging at 12000rpm for 10min, discarding the supernatant, washing the precipitate with DEPC water-prepared 75% alcohol once, centrifuging at 12000rpm for 5min, discarding the supernatant, airing for 10min, adding 20 mu L of DEPC water to dissolve RNA, and measuring the concentration of the RNA by using a Nano Drop 2000. After reverse transcription in 500 ng/10. Mu.L reaction system per sample, 5-fold DEPC water was added for dilution, and then real-time fluorescent quantitative PCR was performed with GAPDH gene as an internal reference, and the expression levels of the osteogenic related genes OCN, BSP and RUNX2 were determined, and the results are shown in FIGS. 6 to 8.
As can be seen from FIGS. 6 to 8, the low, medium and high dose groups each have the ability to induce differentiation of H-BMSC cells (H group) and mouse parietal anterior bone MC3T3-E1Subclone 14 cells (M group) into osteoblasts, which is shown to enhance the expression level of osteogenic related genes such as OCN, BSP and RUNX2, and the effect of the high dose is better, as compared with the control group. As shown in FIG. 6, the amounts of OCN expressed in the H-BMSC cells of the low, medium and high dose groups were 1.7, 2.3 and 2.8 times that of the control group, respectively, and the amounts of OCN expressed in the MC3T3-E1Subclone 14 cells of the low, medium and high dose groups were 1.9, 2.7 and 3.1 times that of the control group, respectively. As shown in FIG. 7, the expression levels of BSP in the H-BMSC cells in the low, medium and high dose groups were 2.2, 3.3 and 3.9 times that in the control group, respectively, and the expression levels of BSP in the MC3T3-E1Subclone 14 cells in the low, medium and high dose groups were 1.9, 2.8 and 3.2 times that in the control group, respectively. As shown in FIG. 8, the expression levels of RUNX2 in the low, medium and high dose groups H-BMSC were 2.9, 3.6 and 4.0 times that in the control group, respectively, and the expression levels of RUNX2 in the low, medium and high dose groups MC3T3-E1Subclone 14 were 2.4, 2.8 and 3.2 times that in the control group, respectively.
The significant differences in the figures are expressed as: "#" and "x" indicate comparison to the H control group and the M control group, respectively, wherein "#" and "x" < 0.05; "#" and "x" < 0.01; "# #" and "x" < 0.001; the analysis method adopted is independent sample T test. EXAMPLE 3 anti-osteoporosis Effect of N-acetyl-D-mannosamine on model mice with osteoporosis
The 32C 57BL/6J mice were divided into 4 groups of 8 mice each, which were divided into a sham-operated group (control group), a model group, a low-dose N-acetyl-D-mannosamine-treated group and a high-dose N-acetyl-D-mannosamine-treated group.
In the model group, the low-dose N-acetyl-D-mannosamine-treated group and the high-dose N-acetyl-D-mannosamine-treated group, when the mice were subjected to bilateral ovariectomy surgery, isoflurane was inhaled for anesthesia (1L/min oxygen+5% isoflurane for anesthesia induction, 0.4L/min+2.5% isoflurane for anesthesia maintenance), then the mice were fixed, sterilized (mice were subjected to lateral recumbent position, alcohol iodophor for sterilization of dorsal and ventral skin), and then subjected to ovariectomy surgery (dehairing, 1-2cm skin was cut, round-headed scissors were inserted between skin and muscle, and expanded while being separated, clamped with skin forceps, myometrium was seen from the wound, lumbar muscle was cut 1cm away from the spinal column, adipose tissue wrapped around the ovaries was immediately visible, and uterine horns tightly connected to the ovaries were gently clamped with forceps, uterine horns were ligated at the upper and lower fallopian tube sites of the uterine horns, and the ovariectomy was cut off, and examined for bleeding, the presence of adipose tissue was pushed back to the skin layer, and the skin layer was sutured together. The sham surgical group cuts fat of the same quality around the ovaries as the ovaries, and the wound is sutured.
Each group of mice was perfused daily at 10 days post-surgery, with model and sham groups perfused with PBS, and the experimental groups were perfused with 1mg/kg of N-acetyl-D-mannosamine dissolved in PBS at a low dose and 10mg/kg of N-acetyl-D-mannosamine dissolved in PBS at a high dose. After 6 weeks of continuous gavage, mice were euthanized, harvested from bilateral femur and fixed in 4% paraformaldehyde. The fixed tissue was photographed using micro-CT and analyzed with corresponding software. The femur CT results, bone mass, trabecular bone gap, and trabecular bone number statistics are shown in fig. 9-13, respectively. ELISA detection results of the serum I-type collagen N-terminal propeptide PINP and serum bone alkaline phosphatase BALP, and the serum I-type collagen C-terminal peptide CTX-1 and tartrate-resistant acid phosphatase TRAP, which are markers of bone resorption, are shown in FIGS. 14-17, respectively.
Table 2 grouping of mice
As can be seen from fig. 9-13: the bone mass comparison of the sham operation group and the model group has obvious difference, the bone mass (BV/TV, BS/TV) and the bone trabecular number (Tb.n) of the sham operation group are obviously higher than those of the model group, and the bone trabecular clearance (Tb.Sp) is obviously lower than those of the model group, which indicates that the modeling is successful; compared with the model group, the bone mass (BV/TV, BS/TV) of the low-dose group and the high-dose group of the N-acetyl-D-mannosamine intervention is obviously improved, the effect of the high dose is better, and the level of the control group is reached. In vivo animal experiments prove that the N-acetyl-D-mannosamine has the effect of promoting bone formation and can be used for preventing and treating osteoporosis. The significant differences in the figures are expressed as: "#" and "x" represent comparisons with control and model groups, respectively, where "#" and "x" < 0.05; "#" and "x" < 0.01; "# #" and "x" < 0.001; the analysis method adopted is independent sample T test.
As can be seen from fig. 14-17: the serum bone formation markers and bone resorption markers of the sham surgery group were significantly different from those of the model group, the bone formation markers PINP and BALP of the sham surgery group were significantly higher than those of the model group, and the bone resorption markers CTX-1 and TRAP were significantly lower than those of the model group. Compared with the model group, the levels of bone formation markers PINP and BALP of the low-dose group and the high-dose group of N-acetyl-D-mannosamine intervention are obviously improved, the levels of bone resorption markers CTX-1 and TRAP are obviously reduced, and the effect of the high-dose group is better. Further proves that the N-acetyl-D-mannosamine has the effect of promoting bone formation and can be used for preventing and treating osteoporosis. The significant differences in the figures are expressed as: "#" and "x" represent comparisons with control and model groups, respectively, where "#" and "x" < 0.05; "#" and "x" < 0.01; "# #" and "x" < 0.001; the analysis method adopted is independent sample T test.
According to the invention, through drug administration research on C57 mice and osteoblast differentiation capability research on human mesenchymal stem cells H-BMSC and mouse cranium top anterior bone MC3T3-E1Subclone 14 cells, N-acetyl-D-mannosamine is determined to be used for promoting growth and development of teenagers bones and preventing or treating osteoporosis.
The applicant states that the present invention is illustrated by the above examples of the use of N-acetyl-D-mannosamine of the present invention in the preparation of medicaments or functional foods for promoting bone growth and development in adolescents and for preventing osteoporosis, but the present invention is not limited to, i.e. does not mean that the present invention must be practiced in dependence on the above examples. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., fall within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, in the above-described embodiments, the specific features described above may be combined in any suitable manner without contradiction, and various possible combinations are not described separately for avoiding unnecessary repetition.
While the invention has been described with reference to the preferred embodiments, it is not limited thereto, and various changes and modifications can be made therein by those skilled in the art without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (10)
- Use of N-acetyl-D-mannosamine or a pharmaceutically acceptable salt thereof for the preparation of a product for promoting bone growth and/or for alleviating and/or treating bone diseases, said N-acetyl-D-mannosamine having the structural formula:
- 2. the use of claim 1, wherein the promotion of bone growth comprises promotion of adolescent bone growth.
- 3. The use according to claim 1, wherein the bone disease comprises osteomalacia, rickets, osteopenia or osteoporosis.
- 4. The use according to claim 1, wherein the product comprises a medicament or a food product.
- 5. The use according to claim 4, wherein the pharmaceutical dosage form comprises any one of suspension, granule, capsule, powder, tablet, emulsion, solution, drop pill, injection, suppository, enema, aerosol, patch or drop.
- 6. The use according to claim 4, wherein the medicament further comprises pharmaceutically acceptable excipients.
- 7. The use according to claim 6, wherein the adjuvant comprises any one or a combination of at least two of a carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, co-solvent, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH regulator, antioxidant, bacteriostat or buffer.
- 8. The use according to claim 4, wherein the food product comprises a solid food product, a liquid food product or a semi-solid food product.
- 9. The use according to claim 4, wherein the food product comprises a dairy product, a soy product or a fruit and vegetable product.
- 10. The use according to claim 1, wherein the promotion of bone growth, and/or alleviation and/or treatment of bone diseases comprises the effect of at least one of the following (a) - (e):(a) Enhancing alkaline phosphatase activity of bone marrow mesenchymal stem cells and/or cranio-parietal preastes cells, and/or osteogenic gene RUNX2, OCN, BSP expression level, and/or degree of calcification, and/or osteogenic differentiation;(b) Increasing serum bone formation markers PINP and/or BALP content;(c) Reducing the content of serum bone resorption markers CTX-1 and/or TRAP;(d) Increasing bone mass and/or the number of bone trabeculae;(e) Reducing bone trabecular clearance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311276869.4A CN117137924A (en) | 2023-09-28 | 2023-09-28 | Application of N-acetyl-D-mannosamine in preparation of food and medicine for promoting bone growth |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311276869.4A CN117137924A (en) | 2023-09-28 | 2023-09-28 | Application of N-acetyl-D-mannosamine in preparation of food and medicine for promoting bone growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117137924A true CN117137924A (en) | 2023-12-01 |
Family
ID=88902763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311276869.4A Pending CN117137924A (en) | 2023-09-28 | 2023-09-28 | Application of N-acetyl-D-mannosamine in preparation of food and medicine for promoting bone growth |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117137924A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008342713A1 (en) * | 2007-12-28 | 2009-07-09 | Bioiberica, S.A. | Composition for the treatment of osteoarthritis |
| US20140349964A1 (en) * | 2011-09-29 | 2014-11-27 | The University Of Tokyo | Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder |
| CN107407673A (en) * | 2015-01-24 | 2017-11-28 | 中央研究院 | Novel poly- candy conjugate and its application method |
| WO2021183819A1 (en) * | 2020-03-13 | 2021-09-16 | Acceleron Pharma Inc. | Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions |
| CN113662949A (en) * | 2021-10-08 | 2021-11-19 | 中国农业科学院兰州兽医研究所 | Application of N-acetyl-D-mannosamine in preparation of antiviral drugs |
-
2023
- 2023-09-28 CN CN202311276869.4A patent/CN117137924A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008342713A1 (en) * | 2007-12-28 | 2009-07-09 | Bioiberica, S.A. | Composition for the treatment of osteoarthritis |
| US20100286086A1 (en) * | 2007-12-28 | 2010-11-11 | Bioiberica, S.A. | Composition for the treatment of osteoarthritis |
| US20140349964A1 (en) * | 2011-09-29 | 2014-11-27 | The University Of Tokyo | Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder |
| CN107407673A (en) * | 2015-01-24 | 2017-11-28 | 中央研究院 | Novel poly- candy conjugate and its application method |
| WO2021183819A1 (en) * | 2020-03-13 | 2021-09-16 | Acceleron Pharma Inc. | Single-arm actriia and actriib heteromultimers and methods for treating renal diseases or conditions |
| CN113662949A (en) * | 2021-10-08 | 2021-11-19 | 中国农业科学院兰州兽医研究所 | Application of N-acetyl-D-mannosamine in preparation of antiviral drugs |
Non-Patent Citations (6)
| Title |
|---|
| DU J, YUE K，等: "Crucial roles of a novel exoskeletal-derived lectin in innate immunity of the oriental river prawn, Macrobrachium nipponense", J FISH DIS, vol. 45, no. 5, pages 717 - 728 * |
| SCHMIDT M，等: "The fecal microbiome and metabolome differs between dogs fed Bones and Raw Food (BARF) diets and dogs fed commercial diets", PLOS ONE, vol. 13, no. 8, pages 1 - 20 * |
| 张志毅;: "再论风湿寒性关节痛", 内科急危重症杂志, no. 02, pages 59 - 61 * |
| 泰山健康: "n乙酰甘露糖氨（N-乙酰甘露糖氨：一种常见参与糖代谢的化合物）", pages 3 - 4, Retrieved from the Internet <URL:https://www.dxmwx.com/lzbzf/guanjie/44700.html> * |
| 闫德祺;闫英选;孙朝阳;宋继祖;罗金宝;: "骨髓间充质干细胞的研究进展", 中国当代医药, no. 24, pages 25 - 27 * |
| 马鞍山市天泰生物科技: "N-乙酰-D-甘露糖胺的作用及注意事项", pages 5 - 7, Retrieved from the Internet <URL:https://baijiahao.baidu.com/s?id=1767917798776652429&wfr=spider&for=pc> * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017394752B2 (en) | Composition for preventing or treating osteoarthritis containing sialyllactose or salt thereof as active ingredient | |
| US20130072466A1 (en) | Composition containing placenta extracts | |
| CN110393728B (en) | Lactobacillus, pharmaceutical composition thereof and use of edible composition in treating, preventing or improving bone diseases | |
| Wu et al. | The antiosteoporotic effects of Cheonggukjang containing vitamin k2 (menaquinone-7) in ovariectomized rats | |
| Mohamed et al. | The effects of Cosmos caudatus on structural bone histomorphometry in ovariectomized rats | |
| CN115944643A (en) | Application of sialic acid in preparing anti-osteoporosis medicine and food | |
| CN117137924A (en) | Application of N-acetyl-D-mannosamine in preparation of food and medicine for promoting bone growth | |
| EP3714885A2 (en) | Composition for preventing, alleviating, or treating bone loss diseases, comprising cyclo(his-pro) (chp) | |
| CN110934883A (en) | Naringin preparation for improving male osteoporosis and preventing fracture | |
| KR102276379B1 (en) | Composition for Preventing or Treating Bone Diseases Comprising IF1 | |
| CN113082059B (en) | Composition for preventing and treating osteoporosis and preparation method and application thereof | |
| EP3626728A1 (en) | Peptide for inhibiting bone resorption | |
| KR101790031B1 (en) | Pharmaceutical composition for preventing or treating women osteoporosis caused by menopause or ovariectomy osteoporosis comprising panax ginseng extracts, paeonia lactiflora extracts, glycyrrhiza uralensis extracts and chitosan | |
| CN117503789A (en) | Application of CMP-Neu5Ac in preparation of food and medicine for promoting bone growth | |
| KR101120499B1 (en) | Composition For Preventing And Treating Bone Diseases | |
| EP4327816A1 (en) | Method for promoting bone healing using lactiplantibacillus plantarum twk10 | |
| CN110693035A (en) | Peptide-containing composition for osteoporosis people to eat and application thereof | |
| CN108619420A (en) | Include the prevention, improvement or therapeutic composition of coix seed and capillary extract as the precocious puberty of active ingredient | |
| US20230321155A1 (en) | Use of Cell-Free Fat Extract for Treating Osteoporosis | |
| CN114042146B (en) | Bovine bone peptide composition and application thereof in preparation of medicines for regulating intestinal flora and preventing and treating osteoporosis | |
| TWI574696B (en) | Novel protein material | |
| EP3970735A1 (en) | Use of composition for preventing, ameliorating, or treating bone loss disorders, comprising cyclo-hispro (chp) and parathyroid hormone | |
| CN117085030A (en) | Application of pinoresinol-4-O-beta-D-glucopyranoside in preparation of medicines for treating or preventing osteoporosis | |
| US20240016788A1 (en) | Pharmaceutical composition for preventing or treating diabetic and postmenopausal osteoporosis, containing adiporon | |
| Bieńko et al. | Densitometric, tomographic and mechanical parameters of the female Wistar rat skeletal system after lactoferrin and colostrum treatment in the condition of gonadectomy-induced osteopenia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |